• Genmab flagged 23 oncology abstracts for upcoming presentation or publication at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, followed by the EHA 2026 Congress in Stockholm from June 11 to June 14.
• The most material readouts are slated for oral sessions, including full Phase 3 results from EPCORE DLBCL-1 comparing epcoritamab monotherapy with investigator’s choice chemoimmunotherapy in relapsed or refractory large B-cell lymphoma.
• Additional Phase 3 data will be presented from EPCORE FL-1, positioning epcoritamab in combination with lenalidomide and rituximab versus the comparator regimen in relapsed or refractory follicular lymphoma.
• Genmab also outlined late-stage trial activity for rinatabart sesutecan in endometrial cancer and ovarian cancer, alongside a Phase 2 study of petosemtamab with pembrolizumab in first-line PD-L1 high metastatic non-small cell lung cancer.
• The update points to a broader push to expand epcoritamab use across earlier lines, outpatient settings, combinations, and fixed-duration regimens, with multiple datasets due in the coming weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211700OMX_____CNEWS_EN_GNW1001183149_en) on May 21, 2026, and is solely responsible for the information contained therein.